Cannabis
Leafreport Releases Findings From Pet CBD Report Showing 56 Percent of Products Have Inaccurate Label Claims
More Than Half of All Pet CBD Products Contain Incorrect Amount of CBD, According to Industry Watchdog Website
TEL AVIV, Israel, May 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Leafreport.com, the CBD industry’s peer-reviewed watchdog website, announced today the results from a comprehensive review of pet cannabidiol (CBD) products from a variety of brands aimed at verifying if the label claims being made about potency were correct. The report showed that 56% of brands contained an incorrect amount of CBD and that many also contained no THC despite being labeled as full-spectrum CBD.
In total, only 24 of the 55 products tested (44%) contained the advertised amount of CBD. The rest were off by anywhere from 10.2% to 98.5% from the label. Notably, 56% (31) of the tested products had CBD levels that differed from the label by more than the acceptable 10% variance. Most of the products (58%) had more CBD than advertised. Of the total tested products, 22 had no THC, despite companies claiming they contained full-spectrum CBD. Only 24 (44%) of the tested products had CBD levels within 10% of the label, which is required for an “A” rating.
“You’re far more likely to find a high-quality CBD product today than several years ago. However, there’s still room to improve. One lingering problem is that many products don’t contain the correct amount of CBD,” said Lital Shafir, the head of product at Leafreport. “Testing to ensure the potency of your product is accurate is a fundamental aspect of brand integrity. There have been many cases of companies selling products that contain little to no CBD — that’s why third party testing is so critical for brands in this industry. Our aim is that regular reports such as Leafreport’s will help CBD consumers become more savvy and allows us to act as sort of a watchdog for the industry as a whole.”
Among other key findings exposed by the report were that, overall, pet edibles and topicals are usually less accurate than oils and tinctures. In addition, despite scoring well for tinctures, many companies received a poor score for their edible pet products.
The independent testing was completed at Canalysis Laboratories, a Las Vegas-based cannabis testing lab. The report also includes details about CBD prices to help consumers find the best deal and save money.
This report is one of many completed by Leafreport aimed at informing consumers about various aspects of the CBD industry. These reports include recent deep-dives into topicals, edibles, beverages, and more.
Click here to read the full report from Leafreport: https://www.leafreport.com/education/leafreport-releases-findings-from-pet-cbd-report-showing-56-of-products-have-inaccurate-label-claims-10676
Visit Leafreport.com for additional reports and product information for consumers.
About Leafreport: Leafreport is a science-based, peer-reviewed website designed to help consumers navigate the landscape of CBD. The company’s mission is to introduce transparency into the CBD industry through its patient-focused, educational content and medical reviews. The company medical review team consists of physicians, chemists, nutritionists, pharmacists, chemists and naturopaths.
Contacts:
Lital Shafir
Head of Product
Kyle Porter
CMW Media
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE3 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace